Cure8 news brief
Positive results and a planned Phase 2b study suggest ontunisertib is progressing in development for fibrostenosing Crohn’s disease — a condition with limited targeted therapies for intestinal fibrosis.
Adult patients with fibrostenosing Crohn’s disease, IBD clinicians, and researchers following new anti‑fibrotic therapies and clinical trials.
AgomAb filed a Form 6‑K summarizing a press release that the STENOVA open‑label extension produced positive
The source is a company SEC filing and press release summary; the extracted article does not include detailed trial data, safety results, or peer‑reviewed analysis. Forward‑looking statements are subject to change.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Treating fibrotic strictures would address an unmet need in Crohn’s disease — current approved drugs target inflammation, not established fibrosis. Positive Phase 2a signals could eventually lead to a new pharmacologic...
If you have fibrostenosing Crohn’s disease, this investigational oral drug is being studied specifically for strictures — the company reports high CDAI remission in the extension and plans a larger randomized study...
The report suggests an investigational, gut-restricted ALK5 inhibitor (ontunisertib) had sustained symptom control, high remission rates, and few procedures or surgeries in an open-label extension for fibrostenosing...
